DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for prostatic adenoma — screening already-approved drugs against its 45-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleProstatic adenoma maps to a 45-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for prostatic adenoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
protein tyrosine phosphatase receptor type D (PTPRD) — PTPRD is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet flcdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2YD6 · 1.35 Å · ligand CITRATE ANION (FLC). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Canadian Urological Association Journal · 2013 · 0 citations · open access
Podium Session 2: BPH/Voiding Dysfunction
AbstractWe report the first single center, prospective randomized study comparing HoLEP and PVP/HPS for the surgical treatment of large prostatic adenoma >60 mL. Methods: Eighty patients with large prostatic adenoma (62-160 mL) were randomly assigned to surgical treatment with HoLEP (n=43) or PVP (n=37). International Prostate Symptom score (IPSS), International Index of Erectile Function (IIEF-5), Maximum Flow Rate (Qmax), Post void Residual Urine (PVR), serum PSA and transrectal ultrasound volumes (TRUS) were recorded. Operative data and number of fibers used were also recorded. Complications were defined using Clavien classification. Patients were evaluated at 1, 3 and 6 months, and at 1 year follow up. Results: Baseline characteristics of both groups were similar; as the mean TRUS volume was 91 and 89 mL (p=0.6), Qmax was 8 and 9 mL/sec (p=0.3) and PVR was 268 and 272 mL (p=0.2), for HoLEP and PVP groups respectively. Operative time and catheter removal time were nearly equal in both groups (p=0.7 and 0.1 respectively). Eight cases from the PVP group were converted into either TURP or HoLEP intraoperatively, due to bleeding. Although we conducted the analysis according to the intent to treat, including the PVP converted cases in the PVP group, a significantly higher Qmax and lower PVR were noticed in HoLEP group during the entire period of follow up; however, no significant differences in IPSS, QOL or IIEF were detected. The percentage of prostate volume and serum PSA decrease was 78% and 88% in HoLEP group and 52% and 60% in PVP group respectively (p<0.0001 and 0.05 respectively). According to Clavien classification, 9 patients (11%) had grade 3 complications; 3 of them in HoLEP and 6 in PVP groups. Conclusion: Both HoLEP and PVP are effective modalities for treatment of LUTS due to large size prostatic adenoma, with a reasonable rate of complications. Early functional results (Qmax and PVR) of HoLEP appear to be superior to PVP, although the quality of life and IPSS scores were nearly equal postoperatively in both groups. In our hands; cases intended to be treated by PVP had 22% risk of conversion to other modalities. This could reflect our determination to vaporize to the capsule in all PVP cases.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
